BLSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
BlossomHill Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 18, 2026
$14.16+0.22 (+1.58%)
Close on Oct 19, 2026
- Market cap
- $38.43M
- P/E (TTM)
- –
- Dividend yield
- –
About BlossomHill Therapeutics
Pharmaceutical Preparations, SIC 2834
BlossomHill Therapeutics, Inc. is listed on Nasdaq under the ticker BLSM, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- BlossomHill Therapeutics, Inc.
- Headquarters
- San Diego, CA
- Address
- 10255 Science Center Drive, Suite 200
- Phone
- (858) 732-3880
- Website
- bhtherapeutics.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- BLSM
- Exchange
- Nasdaq
- IPO date
- Aug 7, 2026
- Shares outstanding
- 32M, Sep 16, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1839970
- CUSIP
- 095130100
- ISIN
- US0951301003
- EIN
- 85-1578711
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jingrong Jean Cui | President and CEO, Director | 3,973,138 |
| Yishan Li | Executive Chairman, Director | 3,859,703 |
| Vincent Paul Liptak | General Counsel | 134,099 |
| Jason A. Keyes | Chief Financial Officer | 700 |
| Geoffrey Raymond Oxnard | Chief Medical Officer | 17,785 |
| Advisors Llc Orbimed | Director | – |
| Capital GP VIII LLC OrbiMed | Director | 2,714,279 |
| Carl L. Gordon | Director | 2,714,279 |
| John P. Schmid | Director | 6,000 |
| Sundeep Agrawal | Director | 578,524 |
| Bihua Chen | Director | – |
| Sheila Gujrathi | Director | 90,160 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 7, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 4, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |